5-MeO-DMT

5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine) is an extremely powerful psychedelic tryptamine. In the psychedelic counterculture, it is sometimes nicknamed The God Molecule, in reference to the phenomenology of non-dual unity and luminous void that it induces. Its pharmacological profile is distinct from that of N,N-DMT: it is characterised by a dominant 5-HT1A affinity, with 5-HT2A activity. It is present in the secretion of the toad Incilius alvarius (formerly Bufo alvarius) and in certain plants.

Pharmacology

5-MeO-DMT is a tryptaminergic agonist with a profile inverted relative to N,N-DMT: it shows a strong 5-HT1A affinity, with 5-HT2A and 5-HT2C activity, as well as at the σ1 and TAAR1 receptors. As a substrate of MAO-A, it is inactive by the oral route when taken alone.

The 5-HT1A receptor is the major signature of 5-MeO: it underlies dissolution, emptiness and a paradoxical anxiolysis. The 5-HT2A receptor provides the psychedelic component and the collapse of the self-model. The σ1 and TAAR1 receptors may contribute to plasticity and neuromodulation. The pharmacological specificity lies in this 5-HT1A / 5-HT2A ratio, inverted relative to N,N-DMT.

Mechanisms

At the level of brain networks, 5-MeO-DMT causes a rapid collapse of the boundaries of the self, a disintegration of the default mode network (DMN) and a profound alteration of perceptual integration. 5-MeO tends less towards the production of content than towards the erasure of content.

One observes a marked decrease in DMN coherence, an increase in brain entropy, an alteration of self-models and of the subject / object separation, and a marked alpha suppression, with an EEG dynamics distinct from that of N,N-DMT. According to a phenomenological hypothesis, the cortical dissolution of the self may converge with intense interoceptive signals, reinforcing the impression of real death. The corresponding phenomenology overlaps with the territory that the N,N-DMT mapping identifies as the deepest threshold (collapse of the residual observer).

Phenomenology

Functionally, the experience is brief, often of extreme phenomenological intensity, with a bimodality of valence. It is characterised by a complete dissolution of the ego and a non-duality, the perception of a luminous void or of a limitless consciousness.

Two poles coexist: a luminous pole (peace, unconditional love, unity) and an annihilation pole (death experienced as real, possible ontological terror). Temporality is abolished or undecidable. In its prototypical form, a distinctive feature is the near-absence of complex visual content or of entities, in contrast to N,N-DMT (see the nuance below).

Typical subjective effects include an ego dissolution and a total loss of the sense of self, unity and a centreless consciousness, a profound peace, a bliss and an unconditional love, a void and a white light, an ineffability, an ego death experienced as real, all within a very brief but potentially overwhelming experience.

5-MeO-DMT occupies a singular place in the psychedelic repertoire: a phenomenology of erasure rather than of replacement, an extreme subjective intensity, and a physiological dangerousness clearly higher than that of the classic psychedelics. It is not a stronger N,N-DMT, but a different molecule, with its own pharmacological and experiential profile. 5-MeO-DMT does not show more content: it tends towards less content, up to the void or total erasure. It is thus the prototypical molecule of a territory occasionally reached under high-dose N,N-DMT (see the Breakthrough under N,N-DMT article).

Beyond the prototypical opposition

5-MeO is readily summed up as a pure whiteness, a contentless ego death, by contrast with the entities of N,N-DMT. That description targets a prototypical pole, an idealised limit, more than an invariant of every session.

Testimonies in fact describe a range: a luminous form, waves of love or relational warmth, geometric or near-figurative content, re-entry visions, especially on the come-up, on the way down, or below the full-release threshold. The total white-out is the limit-case, not the rule. The bimodality of valence (luminous union or annihilation terror) already shows that this is not a flat, uniform nothingness, and the boundary with the N,N-DMT territory is porous (the convergence at the deepest threshold, noted above, runs both ways).

The ego death of 5-MeO is above all of a different nature from that of N,N-DMT: an erasure toward a centreless field (monadic ownerlessness) rather than a relational dissolution by co-emergence. To oppose void and entities here is to mistake two forms of self-dissolution for dissolution versus non-dissolution. For integration, expecting only the void can lead one to miss, or to mishandle, the dimensions of form and relation that also arise.

Duration and tolerance

Vaporised or smoked, the effect begins within 20 to 60 seconds, peaks within 1 to 3 minutes, has a plateau of 5 to 15 minutes, then a return within 30 to 120 minutes. A phase of immobility at the peak is frequent (2 to 5 minutes). By the oral route, it is inactive without an MAOI.

Acute tolerance is relatively low, and closely spaced doses are sometimes still active. There is a cross-tolerance with other 5-HT2A agonists (LSD, psilocybin, N,N-DMT). It is recommended to space sessions widely apart.

Harm reduction

5-MeO-DMT is probably the most physiologically dangerous substance of the classic psychedelic repertoire. Tachycardia, vasoconstriction and an arrhythmogenic risk are described, as well as documented cases of cardiac arrest, asphyxia and serotonin syndrome. Major interactions involve SSRIs, MAOIs, tramadol, lithium, triptans and DXM. Absolute contraindications include uncontrolled cardiovascular disease and a history of psychosis. Supervision is absolutely required: never use it alone.

5-MeO-DMT and N,N-DMT have inverted pharmacological profiles (1A / 2A), with different prototypical phenomenologies that nevertheless converge at the deepest threshold of N,N-DMT. Harvesting from Incilius alvarius raises the issue of a vulnerable species and a controversial exploitation: synthetic production is preferable, for its controlled purity and for health and ethical reasons. 5-MeO-DMT is also present in certain plants (Anadenanthera peregrina, Psychotria viridis, Mimosa tenuiflora, Phalaris), with a dose variability that constitutes a safety concern.

Sources

• Reckweg et al. (2021), first controlled clinical profiles of safety and pharmacokinetics
• GH Research / GH001 clinical development for treatment-resistant depression
• Work on the partial phenomenological convergence with near-death experiences (NDE)
• Data on the EEG dynamics (alpha suppression) observed under 5-MeO-DMT
• Literature on the toxicity and serotonergic interactions of powerful tryptamines